News

Citryll Establishes Scientific Advisory Board for Advancements

Citryll Establishes Scientific Advisory Board for Advancements

Citryll Announces Formation of Scientific Advisory Board

CITRYLL ANNOUNCES FORMATION OF SCIENTIFIC ADVISORY BOARD

Board comprises world-renowned experts in biology, immunology and pathology

Citryll, a biotech company focused on innovative treatments for immune-mediated inflammatory diseases, has announced the establishment of its Scientific Advisory Board (SAB). This Board will offer crucial strategic guidance and scientific advice as Citryll advances the development of its first-in-class monoclonal antibody, CIT-013, aimed at addressing Neutrophil Extracellular Traps (NETs).

Expertise at the Core of the Advisory Board

The formation of this Board comes with the gathering of internationally recognized experts specializing in various aspects of NET biology, pre-clinical development, and immunology. Among the founding members are Dr. Tim Hammond, Professor John Hamilton, Dr. Christian Lood, and Professor Paul Kubes, each renowned for their significant contributions to medical research and drug development.

Welcoming Notable Members

"We are delighted to have such a prestigious group of experts join our Scientific Advisory Board," stated Eric Meldrum, Chief Scientific Officer of Citryll. Their extensive knowledge will be paramount in advancing CIT-013 through its clinical trials focusing on rheumatoid arthritis and hidradenitis suppurativa. With their collaboration, we expect to unlock a wealth of therapeutic potentials targeting extracellular traps in various inflammatory diseases, marking a significant milestone in expanding our advisory network as we pave the way for a Clinical Advisory Board aimed at enhancing our clinical trajectory.

Introducing the Scientific Advisory Board Members

Dr. Tim Hammond, PhD

Bringing over 35 years of expertise in pharmaceutical drug discovery, Dr. Hammond currently serves as Head of Safety across multiple organizations. His past tenure as Vice President of Safety Assessment for AstraZeneca in the UK highlights his remarkable capabilities. An esteemed independent consultant since 2012, he is lauded as a past President of the British Toxicology Society and a Fellow of the Royal College of Pathologists.

Professor John Hamilton, PhD

Prof. Hamilton is globally recognized for his influential research in macrophage biology and inflammation, with a remarkable focus on inflammatory diseases like rheumatoid arthritis. His accolades include significant awards from the Australian Rheumatology Association and the American College of Rheumatology.

Dr. Christian Lood, PhD

Dr. Lood is a leading figure in research on neutrophil function and NET formation, pivotal in understanding autoimmune diseases including systemic lupus erythematosus. He is currently an Associate Professor in the Division of Rheumatology at the University of Washington, dedicating his research to the interplay of neutrophils in various inflammatory conditions.

Professor Paul Kubes, PhD

Known for his groundbreaking work on leukocyte recruitment, Prof. Kubes is a professor at Queen’s University and holds a Canada Excellence Research Chair. His previous role as the Founding Director of the Snyder Institute for Chronic Disease at the University of Calgary underscores his influence in the field of inflammatory diseases.

About Citryll's Mission and Vision

Citryll stands at the forefront of developing transformative treatments targeting inflammatory diseases by focusing on the often-overlooked Neutrophil Extracellular Traps (NETs). This novel approach aims to create potential breakthrough therapies for a range of immune-mediated conditions.

The company is dedicated to advancing its lead product, CIT-013. This unique monoclonal antibody operates through a distinct dual mechanism by enhancing the clearance of existing NETs while inhibiting the formation of new ones.

By effectively targeting this essential driver of inflammation, CIT-013 aspires to provide an innovative and comprehensive treatment for conditions like rheumatoid arthritis and hidradenitis suppurativa, where existing therapies have often not achieved desirable disease management results.

Contact Citryll for More Information

Citryll
Sjoerd van Gorp, COO
Email: info@citryll.com

Citryll Media Contacts
ICR Healthcare
Amber Fennell, Stephanie Cuthbert, Lucy Featherstone
Email: citryll@icrinc.com

Frequently Asked Questions

What is the purpose of Citryll's Scientific Advisory Board?

The Scientific Advisory Board provides strategic guidance and scientific insights to aid in the development of Citryll's therapies, particularly CIT-013.

Who are the members of the Scientific Advisory Board?

The board includes experts such as Dr. Tim Hammond, Professor John Hamilton, Dr. Christian Lood, and Professor Paul Kubes.

What is CIT-013?

CIT-013 is Citryll's first-in-class monoclonal antibody that targets Neutrophil Extracellular Traps to treat inflammatory diseases.

How does CIT-013 work?

CIT-013 enhances the removal of existing NETs and prevents the formation of new ones, aiming to reduce inflammation in patients.

Where can I find more information about Citryll?

You can reach out to Citryll via email at info@citryll.com for detailed inquiries and information.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Anduin Opens Its Investor Portal Beyond Early Users

Updated Category News Views 68

Private-market paperwork has long been a swamp of portals, PDFs, email chains, and somebody chasing down a wire change at the worst possible moment. Anduin is taking a swing at that mess by opening its Investor Portal to all customers after building it with leading asset managers and operating it with their investors. The pitch is sensible: give limited partners one...

Continue Reading
Faex Health Adds Ebola and H. pylori AI Screening Tools

Updated Category News Views 23

A smartphone pointed at a toilet is an awkward place to hunt for medical progress, yet Faex Health is making a serious attempt to turn that daily evidence into an early-warning tool. The company has added investigational pre-screening capabilities for Ebola virus disease and Helicobacter pylori, or H. pylori, bringing its internally validated panel to 18 gastrointestinal...

Continue Reading
Duetti, CesiumAstro, and a Busy NYSE Capital Morning

Updated Category News Views 73

Three very different piles of money are jamming up the November 20 NYSE slate, and that contrast is the whole point. Private music catalogs, space-and-defense communications, and a new stock-and-bond ETF do not belong in the same bucket. Yet all three are competing for investor attention before the opening bell, alongside Danaos Corporation's 20th listing anniversary....

Continue Reading
Cleveland Picks Golden Key for Citywide Leadership Training

Updated Category News Views 215

A Citywide Bet on Better Management Municipal management rarely grabs headlines until something breaks, which is precisely why Cleveland's decision to bring in Golden Key Group deserves a closer look. Announced November 20, 2026, the arrangement calls for GKG to design and deliver a citywide management training program through Cleveland's Department of Personnel and Human...

Continue Reading
Workers Are Burning Savings as Pay Falls Behind Costs

Updated Category News Views 28

Payroll optimism has been ground into dust by the ordinary bills nobody can dodge. Monster's 2026 Cost of Living Report says 93% of employed U.S. workers feel their wages are failing to keep up with costs, barely different from 95% in both 2024 and 2025. That is not a blip, and it is not workers merely grousing about prices. Three years of nearly identical frustration...

Continue Reading
Perigon Builds Its Investment Bench for the Next Leg

Updated Category News Views 91

Perigon is rearranging the engine room before the next growth spurt gets noisy. The firm has named Christopher Broderick Director of Investments and Research, added two trading associates, and put another brick behind the broader operating structure Rafia Hasan has been assembling since taking on the chief operating officer role in August. That may sound like ordinary...

Continue Reading
Fervo IPO Lawsuit Puts 71% Share Collapse in Focus

Updated Category News Views 13

Fervo’s $27 debut has turned into the sort of wreckage IPO buyers dread: shares were alleged to have closed as low as $7.79 when the complaint was filed. That is more than a 71% fall from the May 13, 2026 offering price, and it puts a hard, ugly number beside the new securities class action against the geothermal power developer. More Than a Bad Quarter Is Being Alleged...

Continue Reading
OU's $44.3M Rural Care Plan Targets Oklahoma Care Gaps

Updated Category News Views 0

A Long Drive Is a Brutal Barrier to Care Seventy-five of Oklahoma's 77 counties sit in health professional shortage territory, a figure that ought to stop people cold. It means at least 3,500 patients per provider in those counties. That is not some abstract planning headache. It is the pregnant patient delaying a specialist visit, the family weighing an ambulance ride,...

Continue Reading
KidneyVoter Push Turns Patient Frustration Into Clout

Updated Category News Views 75

A ballot registration drive rarely tells the whole story, but it can reveal where the pressure is building. The American Association of Kidney Patients says its 2026 nonpartisan KidneyVoter™ effort, “50 States in 50 Days,” reached constituencies in every state after launching September 14. That does not produce a clean vote total or prove legislators will suddenly...

Continue Reading
Page Library Grant Makes a Practical Case for Access

Updated Category News Views 56

A library card is not much use if a family cannot reach the help behind it. That plain reality sits at the center of AZ Blue Health Choice’s $10,000 contribution to the Page Public Library Family Resource Center, announced November 20, 2026. This is a modest dollar figure in the grand scheme of health care, but it is aimed at the kind of everyday gaps that can become...

Continue Reading

Top 5 Most Recently Viewed Articles

Analyzing Eli Lilly's Short Interest Trends and Market Sentiment

Updated Category News Views 217

Eli Lilly's Short Interest Overview The short interest for Eli Lilly has noticeably risen by 14.71% since the last report. Currently, there are about 6.27 million shares that have been sold short, which accounts for roughly 0.78% of all regularly traded shares. At the present trading volume, analysts estimate that it would take around 2.41 days for traders to close out...

Continue Reading
Bluevua Expands Reach with Major Online Retailers

Updated Category News Views 21

An Ecommerce Splash for Water Purification Here we are, diving headfirst into yet another tale of market expansion. Bluevua, a name that's been making waves with its reverse osmosis (RO) systems, just secured a roster spot on some of the biggest online retail giants: Target.com, Lowes.com, and Walmart.com. Sure, not every trader is into the nitty-gritty of water...

Continue Reading
Building Products M&A Trends Indicate a Bright Future Ahead

Updated Category News Views 108

Building Products M&A Trends: A Bright Future Ahead The building products mergers and acquisitions (M&A) sector is on the verge of significant growth as we approach 2026. This promising trajectory is rooted in the optimism surrounding the long-term prospects of the U.S. housing market. An analysis provided by experts in the industry illustrates the resilient nature of...

Continue Reading
Recursion to Share Pivotal REC-4881 Data at DDW 2025 Event

Updated Category News Views 499

Recursion to Share Pivotal REC-4881 Data at DDW 2025 Event Recursion, a pioneering clinical stage TechBio company, is set to unveil groundbreaking preliminary data regarding REC-4881 during the prominent Digestive Disease Week (DDW) event in 2025. This gathering is critical as it showcases advancements in gastrointestinal medicine and research. The data will be...

Continue Reading
Reviving the Legend: Remus Bourbon's Babe Ruth Reserve 2025

Updated Category News Views 258

Reviving a Baseball Legend with Remus Bourbon Remus Bourbon is excited to introduce its latest release, the 2025 Babe Ruth Reserve. This special edition pays homage to Babe Ruth, an icon in the world of baseball known as the Sultan of Swat. With only 8,399 bottles available, this limited production truly captures the spirit of both the game and the whiskey-making...

Continue Reading